Overview

Efficacy of Oral Ivabradine in Patients Presenting With NSTEMI

Status:
Completed

Trial end date:
2016-05-01

Target enrollment:
0

Participant gender:
All

Summary

This study aims to evaluate the beneficial effect of heart rate reduction of oral ivabradine in patients presenting with non ST-segment elevation myocardial infarction (NSTEMI) during acute stage post percutaneous coronary intervention versus conventional treatment. Materials and methods: A total of 100 patients admitted to the emergency department, National Heart Institute, Cairo, Egypt were randomized into two groups as follows: Group A: 50 patients with NSTEMI treated with ivabradine (5mg twice daily) in addition to the conventional treatment; Group B: 50 patients with NSTEMI treated with the conventional treatment only. Demographic data, detailed history, clinical examination, chest pain onset, blood pressure, heart rate (HR), temperature and respiratory rate, electrocardiogram (ECG) as well as echocardiography and laboratory investigations were recorded. Patients were monitored for a period of 3-5 days (acute stage).

Phase:

Phase 2/Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Cairo University

Collaborator:

National Heart Institute, Egypt

Criteria

Inclusion Criteria:

- Patients with NSTEMI with normal sinus rhythm and heart rate (HR) more than 70 beats
per minute (bpm) and systolic blood pressure (SBP) >90 mm Hg undergoing PCI

Exclusion Criteria:

- Patients needing urgent cardiac surgery, IV inotropic agents or had a HR less than 60
bpm without any medication.